AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06781541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training was conducted in the gym with progressively increasing resistance from 65% to 75% of the maximum weight (one-repetition maximum (1-RM)). Participants performed 10-13 repetitions of the exercise in one serie. The training was carried out in station form and consisted of 10-13 exercises. There were rest intervals of 60-90 seconds between exercises. As intended, the training was comprehensive, i.e. it affected the muscles of the arms, legs, torso, abdomen and chest.
Study NCT04641975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Oral/ Oral Suspension: Participants with a body weight of ≥ 35 kg are to receive the tablet form of IP unless unable to swallow tablets and will be provided the oral suspension as an alternative. Participants with a body weight \< 35 kg or those who cannot be dosed with the tablet will receive oral suspension.
Study NCT06781541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bungy Pump Exercises
Description: Buny Pump training sessions are conducted by a certified BP instructor leading participants in the outdoor forest of Gdansk. Training is about 60 minutes each time, 3 times a week, a total of 12 weeks. Participants used professional Bungy Pump Pole.
Study NCT06781541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily life
Description: The individuals engaged in routine daily tasks, while being advised against incorporating any supplementary physical exertion.
Study NCT06781541 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional general conditioning training
Description: Training sessions were supervised by a certified instructor. Training was carried out at home with individually adjusted resistance depending on age and health. Participants typically performed 10-13 repetitions of a given exercise. 30-second rest intervals were used between exercises. As intended, the training was comprehensive, i.e. including muscles of the arms, legs, trunk, abdomen, chest, balance and flexibility exercises. Basic training equipment was used during the training.
Study NCT06780527 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 15% Grape seed extract as dentin pretreatment
Description: using proanthocyanidin-rich grape seed extract as a biomodifier for dentin improved the mechanical properties of dental collagen by cross-linking and dehydrating fibrils. This made the collagen substrate more suitable for hybridization. It also acted as a non-specific MMP-inhibitor, protecting exposed collagen fibrils from biodegradation from dentin proteases.
Study NCT06780176 — intervention group
Intervention type: OTHER
Intervention: Biospecimen Collection
Description: Blood collection at baseline and time of surgery
Study NCT06780176 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Surgical Tissue Collection
Description: Tissue collection will be attempted at time of surgery
Study NCT06780176 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey Collection
Description: Survey collection at baseline, post-surgery, at 1, 3 and 5 year follow up visits
Study NCT06781216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Description: It is emphasized that motivational interviewing is a feasible intervention that can be used by various health professionals to optimize clinical outcomes in cancer patients and survivors, helping individuals to better cope with the stress they experience related to cancer and improve their quality of life. Considering the benefits of motivational interviewing on individuals diagnosed with cancer, it is anticipated that the intervention planned in the study will improve coping strategies, reduce post-traumatic stress symptoms, and increase the level of post-traumatic growth in women with endometrial cancer.
Study NCT06782334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMT-116
Description: AMT-116 is an antibody Drug Conjugate (ADC)
Study NCT06782334 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: AMT-116
Description: AMT-116 is an antibody Drug Conjugate (ADC)
Study NCT06781658 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured rehabilitation intervention
Description: Participants will be prescribed a multi-component SRI which will include education, cervical range of motion exercises, progressive neck strengthening exercises, individualised scapular and upper limb strengthening, task specific hand function training and a physical activity behavioural change intervention. The TIDieR checklist has been used to provide a comprehensive description of this complex intervention. (17).
Study NCT06781658 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Surveillance
Description: Participants assigned to the clinical surveillance control group will be invited to attend a single, one to one education session which will be supplemented with a written patient information booklet after which they will be scheduled for a 12 week follow up.
Study NCT05315167 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRJ1-3024
Description: PRJ1-3024 is provided as capsules and is administered orally once a day.
Study NCT06448780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate 20 mg/kg
Description: Following loading dose of 20 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
Study NCT06448780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caffeine citrate 30 mg/kg
Description: Following loading dose of 30 mg/kg of caffeine citrate IV, participants will receive 2 daily doses of 10 mg/kg caffeine citrate IV.
Study NCT04641975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral/ Oral Suspension
Study NCT04905290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left ventricular coronary sinus (BiV) configuration
Description: For subjects with a pacemaker, pacing of the left ventricular coronary sinus only. For subjects with a defibrillator, biventricular pacing of the left ventricular coronary sinus and the right ventricle. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay. Patients with a defibrillator will receive two additional delays LV precedes default by 30ms and LV precedes default by 60ms.
Study NCT04905290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction system pacing-only configuration
Description: Conduction System Pacing (CSP) of the left bundle branch. During the acute protocol, the five AV delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, and default - 60ms AV delay.
Study NCT04905290 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conduction System Pacing Optimized Therapy (CSPOT) configuration
Description: A combination of Left Ventricle pacing and Conduction System Pacing of the left bundle branch. During the acute protocol, the eight delays for this intervention include the default AV delay setting, default + 30 milliseconds (ms) AV delay, default + 60 ms AV delay, default - 30ms AV delay, default - 60ms AV delay, CSP precedes default by 30ms, LV precedes default by 30ms and LV precedes default by 60ms.
Study NCT06332482 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant supported screw retained prosthesis
Description: All patients will receive six maxillary and mandibular implants for full arch screw retained prosthesis
Study NCT05822817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Description: Anesthesia is maintained with inhalation of sevoflurane. The concentration of sevoflurane was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
Study NCT05822817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Anesthesia is maintained with an effect-site target-controlled infusion of propofol (2-6ug/ml) based on the Marsh mode. The concentration of propofol was adjusted to maintain anesthetic depth, aiming for a bispectral index of 40-60.
Study NCT06483217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient-directed follow up
Description: Patients will be instructed to follow up for repeat injection based on bladder symptomatology at their own self-determined time interval.
Study NCT06361446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide 50 MG
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. all patients received zonisamide 100 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of zonisamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT05121038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEND-1
Description: The treatment with CEND-1 will be given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle starting in Cycle 4).
Study NCT05121038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Up to ten (10) participants with cancer that has spread to certain areas of the body and who have a certain gene in the tumor called RAS/BRAF wild type will receive another drug called panitumumab in addition to CEND-1 and FOLFIRINOX.
Study NCT05121038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folfirinox
Description: FOLFIRINOX is a name for a chemotherapy treatment regimen that includes several different drugs that are given in a certain order.~All of these drugs are given as an intravenous (IV) infusion (through a needle in a vein) at the clinic once every 14 days (or Day 1 of every 14-day cycle).~* Oxaliplatin - dose is 85 mg / m2 the infusion takes about 2 hours. then~* Leucovorin - dose is 400 mg / m2 - this is given at same time with irinotecan (below) and the infusion takes about 1.5 hours.~* Irinotecan - dose is 180 mg / m2 - this is given at same time with leucovorin (above), and the infusion takes about 1.5 hours.~then~• Fluorouracil - dose is 2400 mg / m2 - this infusion takes 46 to 48 hours (2 days) with an IV pump done at home.
Study NCT05354284 — intervention group
Intervention type: OTHER
Intervention: online questionnaire
Description: Questionnaire at three timepoints
Study NCT06361446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: The arm will include 300 migraine patients diagnosed according to ICHD3-beta criteria. All patients received propranolol 160 mg daily and acetaminophen 500-1000 mg on migraine attack.~We will assess The change in migraine days per 28 days, the number of migraine days after three months of treatment, and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14). HIT-6 score reduction in each group after three months of treatment. The safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (TEAE) in patients through regular follow-up procedures for three months.
Study NCT05615701 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: EOSedge imaging
Description: Hip X-ray evaluation in an EOSedge imaging for preoperative assessment for hip replacement or revision surgery
Study NCT06567106 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Ultrasound application
Description: Apply ultrasound to the participant within a safe range.
Study NCT06567106 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound application
Description: Apply ultrasound to the participant within a safe range.
Study NCT05004649 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychophysical task
Description: A psychophysical task will be used to measure participants' ability to discriminate the horizontal position of the central object that is presented within the context of background objects in a natural visual scene. The task will be a two-interval forced choice task that presents one stimulus per interval. Between the two stimulus intervals, two masks will be shown in succession at the center of the monitor. The task of the participant will be to determine whether, compared to the central object presented in the first interval, the central object presented in the second interval is to the left or to the right. One of two feedback tones will be presented after the response is entered, indicating whether the participant was correct or incorrect. For trials in which there is no difference in the position of the central object between the two intervals, the response that will receive the correct feedback tone will be randomly selected per trial.
Study NCT06535932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Amara View Minimal Contact Full Face Mask
Description: The Amara View Full-Face Mask is a minimal contact full face mask manufactured by Philips Respironics (Murrysville, PA) that covers the mouth and seals under the nose compared to traditional full-face masks which seal over the nose. The Amara View mask is intended to reduce discomfort on the bridge of the nose. There is no forehead arm, offering patients an enhanced design to keep the field of vision clear.
Study NCT06535932 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: F40 Minimal Contact Full Face Mask
Description: The AirFit F40 is a minimal contact FFM manufactured by ResMed (San Diego, CA) that rests softly and securely under the patients nose and is designed to let patients sleep in any position and move freely throughout the night. The mask consists of three cushion sizes and three headgear sizes. Headgear adjustments can be made with magnetic clips that easily snap on and off.
Study NCT05999916 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized Miamind Neurostimulator
Description: 60 min. 40 Hz max. 1mA / electrode \& total of max. 2 mA across all electrodes. 30- s ramp-up personalised intervention based on individual modelling of electric field distribution to maximise therapeutic effect in the target region. Three target regions, consecutively stimulated (20min each).
Study NCT04899934 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile and technology assisted aftercare
Description: The mobile and technology assisted aftercare consists of mobile mental health professionals who travel to participants to provide mental health services including counseling, navigation of community referrals, motivational interviewing, solution focused therapy, psycho-education, and social support. Participants randomized to this condition will also receive 24/7 access to evidence-based behavioral health mobile applications that are recommended based on the participant's diagnostic status, learning style, and goals. Frequency of app use is up to the participant's discretion. However, during weekly aftercare sessions, the CSS may assist the participant with creation of an app use schedule that is realistic for the participant's needs and treatment goals.
Study NCT04899934 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual services include a personalized discharge plan, a follow up appointment within a month of discharge for evaluation and connection to other agency services if applicable. Some of these services may include outpatient counseling for behavioral and emotional problems, psychiatric services, group therapy, case management, rehabilitation services, homeless recovery services, employment services, medication-assisted treatment, group-based team building activities, primary care clinic, and forensic services. Individuals may also receive ancillary referrals for applicable healthcare services, access to residential and outpatient substance abuse treatment services, and access to a tablet.
Study NCT05856760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sparsentan
Description: Target dose of 400 mg daily
Study NCT05073523 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Diet
Description: All intervention meals consist of five different food groups including fruits, vegetables, legumes, dairy products, and whole grains. Differences in the proportion of these foods in Meal A-C is tested.
Study NCT05579262 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Single-centre, two-arm study involving 16 weeks of beetroot juice supplementation
Study NCT05215496 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-PEG-folate PET/CT scan
Description: A dynamic FR-targeted PET scan, a low-dose CT scan without contrast agents, and a static FR-targeted PET scan will be obtained
Study NCT05281354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal intervention
Description: Treatment to normalise resting energy expenditure according to the observed abnormalities such as anti-inflammatory treatment with Omega 3 in the case of systemic inflammation, treatment with a non-specific beta-blocker such as propanolol in the case of activation of the beta-adrenergic system, appropriate physical activity in the case of sarcopenia, or nutritional support aimed at re-establishing the balance of calorie and protein intake and expenditure, or a combination of these actions
Study NCT00625157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASF 1096 0.5 % cream
Study NCT00625157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASF 1096 placebo cream
Study NCT05283954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination regimen: Fluoxetine, Prednisolone, Ivermectin
Description: Subjects will receive the following treatments:~Fluoxetine 20 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Prednisolone 25 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Ivermectin 3 mg oral tablets: Tablets started right after randomization (Day 0; 400mcg/ kg dosing), administered once a day for 05 consecutive days.
Study NCT05283954 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Combination regimen: Albendazole, Vitamin C
Description: Subjects will receive the following treatments:~Vitamin C 50 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 09 days.~Albendazole 200 mg oral tablets: One tablet right after randomization (Day 0) followed by one daily tablet for the following 04 days.~Vitamin C 50 mg oral tablets: Tablets started right after randomization (Day 0; 130mcg/ kg dosing), administered once a day for 05 consecutive days.
Study NCT06229314 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Inspiratory muscle training
Description: In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.
Study NCT06229314 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: In this study, the preoperative pulmonary function, respiratory and peripheral muscle strengths, functional capacities, and QoL of AIS patients who were eligible for surgery by the physician were evaluated. Subsequently, individuals underwent surgery. Pulmonary function tests and respiratory muscle strength measurements were performed on the patients approximately two days after surgery. Inspiratory Muscle Training was initiated at 60% of the MIP value. IMT was administered using the Powerbreathe device twice a day with 30x2 breaths. The device was adjusted weekly based on the patient\&#39;s current MIP value, and training continued at 60% of the MIP value . The sham group received IMT at 5% of the measured MIP value, with adjustments made weekly, similar to the IMT group. Patients were asked to keep a daily record of their sessions. IMT was administered for a total of 6 weeks. At the end of the sixth week, initial tests and questionnaires were repeated for individuals in both groups.
Study NCT04943549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Patients will be placed in left lateral position. A low-frequency curved array ultrasound transducer will be used. The ultrasound transducer will be placed in a longitudinal orientation 2-3 cm lateral to the midline to identify the hyperechoic line of the transverse process. After identification of muscles superficial to the transverse process and local infiltration of anesthesia into the superficial tissues, a block needle will be inserted in a craniocaudal direction until contact will be achieved with the transverse process where the tip will lay in the interfascial plane below the erector spinae muscle. A small bolus of local anaesthetic should be given through the block needle; the erector spinae muscle should be visualized, separating from the transverse process. A total of 20 mL bupivacaine 0.25% will be injected into the interfacial plane deep to the erector spinae muscle bilaterally. Forty minutes after the ESPB, the cutaneous sensory block will be assessed.